• / Free eNewsletters & Magazine
  • / My Account
Home>Insiders>Thomas H. Lee

Thomas H. Lee

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Onxeo: Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board

    Onxeo: Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board

  2. Between Fed Lift-Off and Living in the New Neutral

    Ceridian CEN is set be acquired after shareholders finally approved the $36 per share offer from Thomas H . Lee Partners and Fidelity National Financial FNF. We expect the deal to be completed before the end of the year.

  3. Radiotherapy, Immunotherapy and DNA Repair Inhibitors: a Winning Combination towards the Oncology of the Future

    Radiotherapy, Immunotherapy and DNA Repair Inhibitors: a Winning Combination towards the Oncology of the Future

©2017 Morningstar Advisor. All right reserved.